search
Back to results

A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Phase 4
Locations
Slovakia
Study Type
Interventional
Intervention
tocilizumab [RoActemra/Actemra]
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult patients >/= 18 years of age
  • moderate to severe active rheumatoid arthritis
  • inadequate response, or intolerance to previous therapy with one or more traditional DMARDs
  • DAS >3.6
  • pneumology examination (including chest x-ray and quantiferon)

Exclusion Criteria:

  • < 18 years of age
  • active infection
  • active tuberculosis
  • uncontrolled hyperlipoproteinaemia
  • demyelinating disorders
  • concomitant anti-TNF drugs
  • history of intestinal ulceration and diverticulitis

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single Arm

Arm Description

Outcomes

Primary Outcome Measures

Percentage of Participants Adherent to Original Treatment
Adherence rate to original treatment according to the protocol included all participants that received the study drug beginning from Week 8 and remaining until the end of the study. This number represents participants with no changes in treatment protocol, participants with treatment discontinuation, and participants with dose reduction, but not participants that withdrew from the study prematurely.
Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason
Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason
Percentage of Participants Withdrawing From the Study Prematurely for Any Reason
Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg

Secondary Outcome Measures

Disease Activity Score Based on 28-Joint Count (DAS28)
DAS28 calculated from the number of swollen joints and tender joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Patient Global Assessment of Pain
Participants were asked to rate their pain using a 0 to 100 mm visual analog scale (VAS), where 0 mm = no pain and 100 mm = worst possible pain. The participant was asked to mark the line corresponding to their perceived level of pain and the distance in mm from the left edge of the scale was measured.
Patient Global Assessment of Disease Activity
The participant's assessment of disease activity was performed using a 100 mm VAS ranging from no activity (0) to maximal activity (100). The participant was asked to mark the line corresponding to their perceived level of disease activity and the distance in mm from the left edge of the scale was measured.
Physician's Global Assessment of Disease Activity
Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The physician was asked to mark the line corresponding to their perceived level of the participant's disease activity and the distance in mm from the left edge of the scale was measured.
Swollen Joint Count (SJC)
The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not swollen or 1=swollen. The total number was calculated from all the joints for a maximum score of 28.
Tender Joint Count (TJC)
The following 28 joints were assessed by the physician for tenderness: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not tender or 1=tender. The total number was calculated from all the joints for a maximum score of 28.
Erythrocyte Sedimentation Rate (ESR)
ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.
C-Reactive Protein (CRP)
CRP is an acute phase protein. Levels of CRP increase with inflammation.
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
Short Form-36 (SF-36)
The SF-36 measures the impact of disease on overall quality of life and consists of 8 subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health.

Full Information

First Posted
November 9, 2009
Last Updated
July 23, 2014
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT01010503
Brief Title
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
Official Title
Evaluation of Adherence and Persistence to Tocilizumab in Combination With Methotrexate or Tocilizumab Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis in Local Environment.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
May 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

5. Study Description

Brief Summary
This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to non-biologic DMARDs. Patients will receive tocilizumab 8 mg/kg as intravenous infusion once every 4 weeks in combination with methotrexate or in case of intolerance to methotrexate as monotherapy. The anticipated time of study treatment is 6 months. The target sample size is 20-50 patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single Arm
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
tocilizumab [RoActemra/Actemra]
Intervention Description
tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
Primary Outcome Measure Information:
Title
Percentage of Participants Adherent to Original Treatment
Description
Adherence rate to original treatment according to the protocol included all participants that received the study drug beginning from Week 8 and remaining until the end of the study. This number represents participants with no changes in treatment protocol, participants with treatment discontinuation, and participants with dose reduction, but not participants that withdrew from the study prematurely.
Time Frame
Week 24
Title
Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Percentage of Participants Withdrawing From the Study Prematurely for Any Reason
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg
Time Frame
Weeks 0, 4, 8, 12, 16, and 20
Secondary Outcome Measure Information:
Title
Disease Activity Score Based on 28-Joint Count (DAS28)
Description
DAS28 calculated from the number of swollen joints and tender joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Time Frame
Weeks 0, 4, 12, and 24
Title
Patient Global Assessment of Pain
Description
Participants were asked to rate their pain using a 0 to 100 mm visual analog scale (VAS), where 0 mm = no pain and 100 mm = worst possible pain. The participant was asked to mark the line corresponding to their perceived level of pain and the distance in mm from the left edge of the scale was measured.
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Patient Global Assessment of Disease Activity
Description
The participant's assessment of disease activity was performed using a 100 mm VAS ranging from no activity (0) to maximal activity (100). The participant was asked to mark the line corresponding to their perceived level of disease activity and the distance in mm from the left edge of the scale was measured.
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Physician's Global Assessment of Disease Activity
Description
Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The physician was asked to mark the line corresponding to their perceived level of the participant's disease activity and the distance in mm from the left edge of the scale was measured.
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Swollen Joint Count (SJC)
Description
The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not swollen or 1=swollen. The total number was calculated from all the joints for a maximum score of 28.
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Tender Joint Count (TJC)
Description
The following 28 joints were assessed by the physician for tenderness: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not tender or 1=tender. The total number was calculated from all the joints for a maximum score of 28.
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Erythrocyte Sedimentation Rate (ESR)
Description
ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.
Time Frame
Weeks 0, 4, 12, 20, and 24
Title
C-Reactive Protein (CRP)
Description
CRP is an acute phase protein. Levels of CRP increase with inflammation.
Time Frame
Weeks 0, 4, 12, 20, and 24
Title
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
Description
The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
Time Frame
Weeks 0, 4, 8, 12, 16, 20, and 24
Title
Short Form-36 (SF-36)
Description
The SF-36 measures the impact of disease on overall quality of life and consists of 8 subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health.
Time Frame
Weeks 0, 12, and 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult patients >/= 18 years of age moderate to severe active rheumatoid arthritis inadequate response, or intolerance to previous therapy with one or more traditional DMARDs DAS >3.6 pneumology examination (including chest x-ray and quantiferon) Exclusion Criteria: < 18 years of age active infection active tuberculosis uncontrolled hyperlipoproteinaemia demyelinating disorders concomitant anti-TNF drugs history of intestinal ulceration and diverticulitis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
City
Piestany
ZIP/Postal Code
921 12
Country
Slovakia

12. IPD Sharing Statement

Learn more about this trial

A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.

We'll reach out to this number within 24 hrs